Business Wire1h
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
News Medical on MSN18h
Salt substitutes may lower stroke recurrence and death risk
Research indicates that salt substitutes reduce stroke recurrence and death risk, offering a safe dietary intervention for ...
The American Journal of Managed Care17h
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...
The American Journal of Managed Care17h
Opportunities for Easing BTK Inhibitor Switches
Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of ...